Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Breakthroughs in Chikungunya Research Spell New Hope for Better Treatment and Protection

Published: Monday, September 24, 2012
Last Updated: Monday, September 24, 2012
Bookmark and Share
A*STAR's SIgN have made great strides in the battle against the infectious disease.

Recent breakthroughs in Chikungunya research spearheaded by scientists at A*STAR's Singapore Immunology Network (SIgN) have made great strides in the battle against the infectious disease.

Working in close collaborations with Singapore clinician-scientists and international researchers, Dr Lisa Ng, Principal Investigator of the Chikungunya research group at SIgN, led the team to discover a direct biomarker which serves as an early and accurate prognosis of patients who have a higher risk of the more severe form of Chikungunya fever (CHIKF).

This means that doctors can now quickly and accurately identify patients at risk, facilitating a more targetted treatment and clinical care at the onset of the disease.

Chikungunya fever, caused by the Chikungunya virus (CHIKV), is a mosquito-borne, infectious disease endemic to Southeast Asia and Africa.

Since its re-emergence in 2005, CHIKV infection has spread to nearly 20 countries to infect millions. Singapore, for instance, was hit twice by Chikungunya fever outbreaks in January and August 2008.

CHIKV infection is characterized by an abrupt onset of fever frequently accompanied by severe muscle and joint pains. Though most patients recover fully within a week, in severe cases, the joint pains may persist for months, or even years.

For individuals with a weak immune system, the disease can result in death. With no clinically-approved vaccine or treatment for Chikungunya fever, it remains a worrying public health problem.

To devise strategies to stop CHIKV transmission, Dr Ng's team collaborated with Professor Leo Yee Sin and Dr Angela Chow, clinician-scientists from the Communicable Disease Centre (CDC) at Tan Tock Seng Hospital, to study how the human body responds to CHIKV infection.

The team conducted a comprehensive study on the antibody response against CHIKV in patients. They discovered that patients who respond to the disease at the onset with high levels of Immunoglobulin G3 (IgG3), a naturally-acquired antibody, are protected from the more severe form of Chikungunya fever, characterized by persistent joint pains.

On the other hand, patients with a delayed IgG3 response generally have less acute symptoms at the start, but are more susceptible to chronic debilitating joint pains at later stage of the disease.

Hence, the IgG3 antibodies serve as a specific biomarker of patients with increased risk of the severe form of the disease.

Collaborating with computational experts from A*STAR's Institute for Infocomm Research (I2R), Dr Ng's team also uncovered that a very small defined segment of the Chikungunya viral protein, named "E2EP3", was able to induce the natural IgG3 protective response in preclinical models.

They found that mice vaccinated with the E2EP3 peptides were protected against CHIKV with significant reduction in viral counts and joint inflammation.

This finding raises hope for a new effective Chikungunya vaccine that can offer protection against Chikungunya virus in the event of an outbreak.

Dr Ng said, "Long-term treatment required for the chronic joint pain in Chikungunya-infected patients places social and economic burden for both patients and the public healthcare system. We are excited that the mechanistic insights gained through our collaborative research with the local hospitals and international research partners have led to discovery of 'new weapons' to tackle Chikungunya more effectively."

Scientific Director of SIgN, Professor Paola Castagnoli said, "With increasing threat of Chikungunya virus infection, particularly in Asia and the Pacific region, this significant breakthrough is a step forward in enhancing our pandemic preparedness against the infectious disease. This is a testament to the successful collaborations between research scientists and clinicians in translating scientific discoveries into impactful healthcare solutions for the benefit of Singapore and beyond."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A*STAR Findings on Breast Cancer Hold Potential for New Treatments
Computational techniques to increase understanding of diseases and improve patient treatments.
Friday, October 30, 2015
A*STAR Scientists Discover Gene Critical for Proper Brain Development
This gene accounts for the size of the human brain and potentially our superior cognitive abilities.
Friday, December 26, 2014
Gene Associated with an Aggressive Breast Cancer Identified
Over-expressed gene in triple negative breast cancer offers new diagnostics for risk assessment.
Wednesday, December 03, 2014
Novel Gene Predicts Both Breast Cancer Relapse and Response to Chemotherapy
A predictive marker discovered by scientists at A*STAR and NUS could help doctors classify breast cancer patients for more effective treatment.
Thursday, August 21, 2014
New Tool to Study Critical Protein Interaction in Cancer Research
A*STAR scientists used fluorescent molecular rotors to study protein-protein interactions involving p53 and MDM2 in cells.
Thursday, July 03, 2014
New Possibilities for Leukaemia Therapy with a Novel Mode of Cancer Cell Recognition
A new class of lipids in human leukaemia cells trigger an immune response to kill the cells.
Thursday, June 26, 2014
Nature and Nurture: Baby's Development is Affected by Genes and Conditions in the Womb
First attempt to discover how genetic and environmental factors affect the human epigenome.
Tuesday, April 29, 2014
Elephant Shark Genome Provides New Insights into Bone Formation in Humans
A*STAR-led international consortium completely decodes the first shark-family member genome.
Thursday, January 09, 2014
A*STAR Scientists Discover Novel Hormone Essential for Heart Development
This unusual discovery could aid cardiac repair and provide new therapies to common heart diseases and hypertension.
Friday, December 06, 2013
A*STAR and NUS Launch Joint Centre
The S$148 million centre will study the role of nutrition and early development in health and disease in Asia.
Thursday, October 10, 2013
Scientists Find a Promising Way To Boost The Body’s Immune Surveillance Via p53
Researchers at A*STAR have discovered a new mechanism involving p53, the famous tumour suppressor, to fight against aggressive cancers.
Thursday, September 26, 2013
Singapore Scientists Discover New RNA Processing Pathway Important in hESCs
Discovery of RNA regulator could lead to a better understanding of diseases like cancer and influenza.
Monday, September 09, 2013
Scientists at GIS Discover Gene that Controls the Birth of Neurons
Discovery of long non-coding RNA's role in neurogenesis may lead to cures for diseases such as Alzheimer's disease.
Thursday, August 29, 2013
A*STAR Scientist Alex Matter Awarded Prestigious Szent-Gyorgyi Prize For Progress In Cancer Research
National Foundation for Cancer Research honours Professor Alex Matter with esteemed award for groundbreaking cancer pill that gives leukaemia patients a new lease of life.
Friday, April 05, 2013
A*STAR Scientists Make Discovery of Cell Nucleus Structure Crucial to Understanding Diseases
Genes relocated from their correct position in the nucleus cause them to malfunction and this may lead to the heart, blood vessels and muscles breaking down.
Friday, February 08, 2013
Scientific News
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Regulatory RNA Essential to DNA Damage Response
Researchers discover a tumour suppressor is stabilized by an RNA molecule, which helps cells respond to DNA damage.
Death-or-Repair Switch Protein Identified
Researchers have identified a protein that plays a key role in the decision process of cell damage repair or cellular suicide.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Wearable Microscope Can Measure Fluorescent Dyes Through Skin
UCLA research could make monitoring disease biomarkers easier and more cost-effective.
“Sixth Sense” More Than a Feeling
NIH study of rare genetic disorder reveals importance of touch and body awareness.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!